-
Mashup Score: 0
More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed. Tabelecleucel (Atara Biotherapeutics) is an allogeneic, nongene-edited, Epstein-Barr virus (EBV)-specific T-cell therapy.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed. Tabelecleucel (Atara Biotherapeutics) is an allogeneic, nongene-edited, Epstein-Barr virus (EBV)-specific T-cell therapy.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Tabelecleucel #CellTherapy a ‘meaningful’ advance for EBV-driven post-transplant lymphoproliferative disease says @SusanProckopMD at #Tandem22 Read more from the phase 3 ALLELE study here: https://t.co/t4ACoCPmM6 #lymphoma @ASTCT @CIBMTR @BostonChildrens @Atarabio
-
-
Mashup Score: 0
More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed. Tabelecleucel (Atara Biotherapeutics) is an allogeneic, nongene-edited, Epstein-Barr virus (EBV)-specific T-cell therapy.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tabelecleucel #CellTherapy a ‘meaningful’ advance for EBV-driven post-transplant lymphoproliferative disease says @SusanProckopMD at #Tandem22 Read more from the phase 3 ALLELE study here: https://t.co/XWQxu00Hbj #lymphoma @ASTCT @CIBMTR @BostonChildrens @Atarabio
-
-
Mashup Score: 2Latest updates on T-cell therapies for non-Hodgkin lymphoma - 3 year(s) ago
Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don't miss our latest podcast on T-cell therapies for non-Hodgkin lymphoma 💊💉 With experts including Jeremy Abramson, Susan Prockop (@SusanProckopMD) & Max Mamonkin (@MaxMamonkin) 👩⚕️👨⚕️ 🎧 Listen now: https://t.co/xGMKVMiESd @VJHemOnc #iwNHL21 #LYMsm #Lymphoma #CaxTx #CART
-
-
Mashup Score: 1Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation - PubMed - 4 year(s) ago
BACKGROUNDAdoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.METHODSWe developed a third-party, allogeneic, of …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#IWD2021 @sloan_kettering study by @SusanProckopMD Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation @jclinicalinvest 12/n https://t.co/g8Uld8cxtH
-
Tabelecleucel #CellTherapy a ‘meaningful’ advance for EBV-driven post-transplant lymphoproliferative disease says @SusanProckopMD at #Tandem22 Read more from the phase 3 ALLELE study here: https://t.co/XWQxu00Hbj #lymphoma @ASTCT @CIBMTR @BostonChildrens @Atarabio